We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » MERGER OF SANOFI-SYNTHELABO, AVENTIS IS PRICE-DRIVEN TREND
MERGER OF SANOFI-SYNTHELABO, AVENTIS IS PRICE-DRIVEN TREND
April 30, 2004
Last week’s announcement that French drugmaker Aventis’ was accepting Sanofi-Synthelabo’s improved stock-and-cash bid is part of a larger market trend being driven by increasing concern over pricing issues, according to industry analysts.